{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:34:30Z","timestamp":1790476470962,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rezafungin is a second\u2010generation, once\u2010weekly echinocandin antifungal approved for the treatment of invasive candidiasis, including candidemia. In phase II\/III studies of rezafungin versus caspofungin, patients with severe hepatic impairment were excluded due to lack of caspofungin data in this population. This open\u2010label, single\u2010dose, phase I study evaluated the pharmacokinetics (primary objective) and safety of rezafungin in subjects with moderate or severe hepatic impairment versus matched, healthy subjects with normal hepatic function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eight subjects each with moderate (Child\u2010Pugh B) or severe (Child\u2010Pugh C) hepatic impairment were matched 1:1 with healthy subjects for age, sex, and body mass index. Each subject received a single 400\u2010mg, intravenous, 1\u2010h infusion of rezafungin. Plasma pharmacokinetic sampling was performed at various time points through 336\u2009h postdose. Pharmacokinetic parameters were derived by non\u2010compartmental analysis. Safety was assessed throughout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All 32 subjects received study treatment and were included in all analyses. Despite overlapping distributions of total plasma concentrations, based on geometric least\u2010squares (LS) mean ratios, the area under the plasma concentration\u2013time curve from time zero (prior to the start of infusion) to infinity (AUC<jats:sub>0\u2013\u221e<\/jats:sub>) was 32% lower in subjects with moderate (LS mean ratio, 67.55; 90% confidence interval [CI]: 53.91, 84.65) and severe (LS mean ratio, 67.84; 90% CI: 57.49, 80.05) hepatic impairment versus matched healthy subjects. The maximum plasma concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) was 12% lower in moderate hepatic impairment and 28% lower in severe hepatic impairment groups. Linear regression showed no significant trend in the degree of hepatic impairment (based on Child\u2010Pugh score) on AUC<jats:sub>0\u2013\u221e<\/jats:sub> or <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Treatment\u2010emergent adverse events were reported in seven subjects (21.9%; three subjects in each of the hepatic impairment groups, and one healthy subject), none of which were severe, serious, or resulted in withdrawal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Rezafungin is well tolerated and can be administered to patients with moderate or severe hepatic impairment without the need for dose adjustment. The modest reduction in exposures in subjects with hepatic impairment is not clinically meaningful and is unlikely to impact efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2943","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T02:25:41Z","timestamp":1717640741000},"page":"435-443","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate\/severe hepatic impairment and matched control subjects"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-9301","authenticated-orcid":false,"given":"Shawn","family":"Flanagan","sequence":"first","affiliation":[{"name":"Cidara Therapeutics, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6717","authenticated-orcid":false,"given":"Voon","family":"Ong","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6416-3314","authenticated-orcid":false,"given":"Thomas","family":"Marbury","sequence":"additional","affiliation":[{"name":"Orlando Clinical Research Center  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Jandourek","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-0396","authenticated-orcid":false,"given":"Ronak G.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, LLC  Parsippany New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sandison","sequence":"additional","affiliation":[{"name":"Cidara Therapeutics, Inc.  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad139"},{"key":"e_1_2_10_3_1","volume-title":"Fungemia Candidiasis","author":"Mora Carpio AL","year":"2023"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx445"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.021"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01572-18"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02154-17"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw214"},{"key":"e_1_2_10_10_1","unstructured":"Melinta Therapeutics LLC.Rezzayo (rezafungin) US prescribing information.2023[Updated March 2023; Cited 2023 August 18]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf"},{"key":"e_1_2_10_11_1","unstructured":"European Commission.Rezafungin acetate product information.2023[Updated December 2023; Cited 2024 January 3]. Available from:https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/html\/o2385.htm"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02324-8"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.89"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01626-16"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00758-17"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-17"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02614-17"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01390-21"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007303764"},{"key":"e_1_2_10_23_1","unstructured":"Merck & Co. Inc.Cancidas (caspofungin) US prescribing information.2022[updated May 2022; cited 2023 August 18]. Available from:https:\/\/www.merck.com\/product\/usa\/pi_circulars\/c\/cancidas\/cancidas_pi.pdf"},{"issue":"2","key":"e_1_2_10_24_1","first-page":"149","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis I","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.891336"},{"key":"e_1_2_10_26_1","unstructured":"European Medicines Agency.Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function.2005[cited 2024 March 11]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010evaluation\u2010pharmacokinetics\u2010medicinal\u2010products\u2010patients\u2010impaired\u2010hepatic\u2010function_en.pdf"},{"key":"e_1_2_10_27_1","unstructured":"US Food and Drug Administration.Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design data analysis and impact on dosing and labeling.2003[cited 2024 March 11]. Available from:https:\/\/www.fda.gov\/media\/71311\/download"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpaic.2020.07.001"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00916-23"},{"key":"e_1_2_10_30_1","unstructured":"US Food and Drug Administration.Center for drug evaluation and research: Rezzayo (rezafungin) integrated review.2022[cited 2024 April 05]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217417Orig1s000IntegratedR.pdf"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02603-17"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00842-21"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9665-6"},{"key":"e_1_2_10_34_1","volume-title":"Use of the Child Pugh Score in Liver Disease","author":"Tsoris A","year":"2023"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1042-z"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297227"},{"key":"e_1_2_10_37_1","unstructured":"Pfizer Injectables.Eraxis (anidulafungin) US prescribing information.2020[updated October 2020; cited 2023 September 18]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021632s030lbl.pdf"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005279580"},{"key":"e_1_2_10_39_1","unstructured":"Astellas Pharma US Inc.Mycamine (micafungin) US prescribing information.2019[updated December 2019; cited 2023 September 18]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021506s023lbl.pdf"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:56Z","timestamp":1761059396000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/phar.2943"],"URL":"https:\/\/doi.org\/10.1002\/phar.2943","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"2024-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}